Jackson Grant Investment Advisers Inc. Cuts Position in Edwards Lifesciences Co. (NYSE:EW)

Jackson Grant Investment Advisers Inc. decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 29.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 385 shares of the medical research company’s stock after selling 163 shares during the period. Jackson Grant Investment Advisers Inc.’s holdings in Edwards Lifesciences were worth $29,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of EW. Sequoia Financial Advisors LLC raised its holdings in Edwards Lifesciences by 11.4% in the first quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock valued at $1,081,000 after buying an additional 941 shares during the period. Zions Bancorporation N.A. raised its stake in shares of Edwards Lifesciences by 34.7% during the first quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock valued at $204,000 after purchasing an additional 448 shares during the period. Covestor Ltd raised its stake in shares of Edwards Lifesciences by 18.2% during the first quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock valued at $144,000 after purchasing an additional 188 shares during the period. Mather Group LLC. raised its stake in shares of Edwards Lifesciences by 53.5% during the first quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock valued at $846,000 after purchasing an additional 2,503 shares during the period. Finally, Mackenzie Financial Corp raised its stake in shares of Edwards Lifesciences by 3.1% during the first quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock valued at $77,173,000 after purchasing an additional 19,798 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $0.51 during midday trading on Friday, hitting $85.94. The company’s stock had a trading volume of 3,895,701 shares, compared to its average volume of 2,826,513. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The stock’s 50-day moving average price is $90.15 and its 200-day moving average price is $78.37. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a market capitalization of $51.73 billion, a PE ratio of 37.37, a price-to-earnings-growth ratio of 4.26 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting the consensus estimate of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same period in the previous year, the business earned $0.64 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. Analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Catherine M. Szyman sold 27,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at approximately $2,980,774.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,004 shares of company stock worth $17,166,254. 1.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on EW. Citigroup lifted their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Stifel Nicolaus lifted their price objective on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. Wells Fargo & Company raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target for the company in a research report on Friday, February 2nd. Royal Bank of Canada raised their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. Finally, Morgan Stanley raised their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $91.73.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.